|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
For both BRCA1 and BRCA2 mutation carriers, none of the smoking-related variables was associated with BC risk, except smoking for more than five years before a first full-term pregnancy (FFTP) when compared to parous women who never smoked.
|
31792088 |
2020 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRCA2 mutation carriers had a significantly higher frequency of CNS metastasis than noncarriers when controlling for breast cancer subtype.
|
31581314 |
2020 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We have successfully identified a novel, germline heterozygous, missense mutation of the gene BRCA2: c.7007G>T, p.R2336L, which is likely to be pathogenic in the proband and her elder sister who both had breast cancer.
|
31782247 |
2020 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our study revealed a potential novel gene and multiple disruptive variants of BRCA2 for breast cancer risk, which may identify high-risk women in Chinese populations.This article is protected by copyright.All rights reserved.
|
31837001 |
2020 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Eight PVs in ATM, BRCA2 (x2), PALB2, RAD51D, BRIP1, and MUTYH (x2) were identified in 7 of 44 individuals with breast cancer (15.9%, 95% CI: 7-30%), whereas none were identified in healthy controls (p = .01).
|
31575519 |
2020 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Poly (ADP-ribose) polymerase (PARP) inhibitors exploit this deficiency through synthetic lethality and have emerged as promising anticancer therapies, especially in breast cancer gene (BRCA1 or BRCA2) mutation carriers.
|
31650446 |
2020 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Approximately 5-10% of breast carcinomas have been related to hereditary conditions and are attributable to pathogenic variants in the BRCA1 and BRCA2 genes, which is referred to as hereditary breast and ovarian cancer (HBOC) syndrome.
|
31786208 |
2020 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Formalin-fixed paraffin-embedded primary tumor tissue from 411 patients with a germline BRCA1 or BRCA2 mutation and diagnosed with early breast cancer was included.
|
30614364 |
2019 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Thus, we conducted a prospective study of the relationship between oophorectomy and the risk of contralateral breast cancer in 1781 BRCA1 and 503 BRCA2 mutation carriers with breast cancer.
|
30756284 |
2019 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations in BRCA1 and BRCA2 are the most prominent cause of breast cancer.
|
30188759 |
2019 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Prevalence of BRCA1 and BRCA2 gene mutations in Chinese patients with high-risk breast cancer.
|
30968603 |
2019 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Because one of the early onset genes in breast cancer is the BRCA2, the presence of any of C and T alleles can have a significant effect on the incidence of the disease.
|
30706682 |
2019 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
With regard to pathological features, familial breast cancers caused by BRCA1 mutations usually differ from those caused by BRCA2 mutations and nonfamilial BCs.
|
30552672 |
2019 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort.
|
30175445 |
2019 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Evaluation should be performed in a patient who has clinical signs or symptoms suggestive of ORS, especially in a premenopausal woman with breast cancer who is treated with an aromatase inhibitor following bilateral salpingo-oophorectomy (BSO), or a woman with a pathogenic variant in BRCA1 or BRCA2 who undergoes BSO for ovarian cancer risk reduction.
|
31273878 |
2019 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Modeling RRSO as a time-varying exposure, there was no association with breast cancer risk overall (hazard ratio [HR] = 1.04, 95% confidence interval [CI] = 0.87 to 1.24) or by tertiles of predicted absolute risk based on family history (HR = 0.68, 95% CI = 0.32 to 1.47, HR = 0.94, 95% CI = 0.70 to 1.26, and HR = 1.10, 95% CI = 0.88 to 1.39, for lowest, middle, and highest tertile of risk, respectively) or for BRCA1 and BRCA2 mutation carriers when examined separately.
|
30496449 |
2019 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
For BRCA mutation carriers, potential augmentation of already elevated breast cancer risk is of great concern.
|
30661763 |
2019 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The expression of P53, RB, BRCA1, and BRCA2 were decreased in patients with HPV-positive breast cancer as compared to HPV-negative breast cancer and healthy controls.(All P-values were less than 0.05).
|
30642295 |
2019 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Three PDX models were used that are characterized by different androgen receptor (AR) expression and different homology directed DNA repair capacities, due to a breast cancer associated two (BRCA2) wild-type or mutated status.
|
30520109 |
2019 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
How do mutations affecting the breast cancer genes BRCA1 and BRCA2 cause cancer susceptibility?
|
31337537 |
2019 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In this Dutch multicenter cohort study, we used multivariable Cox models with BRRM as a time-dependent covariable to estimate the associations between BRRM and the overall and BC-specific mortality rates, separately for BRCA1 and BRCA2 mutation carriers.
|
31302855 |
2019 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the BRCA1 and BRCA2 genes constitute a risk factor for breast cancer development.
|
30293211 |
2019 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in BRCA1 and/or BRCA2 genes (gBRCA1/2m) are associated with an increased risk of breast cancer (BC) and ovarian cancer (OC).
|
30617925 |
2019 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
However, the pathogenic variants in BRCA1 and BRCA2 represent only a third of the causes of hereditary BC (Easton et al. in N Engl J Med 372:2243-2257, 2015).
|
31292799 |
2019 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Breast cancer type 1 and 2 susceptibility protein (BRCA1 and BRCA2) expression and <i>BRCA1/BRCA2</i> mRNA expression were evaluated using immunohistochemistry (IHC) and <i>in-situ</i> hybridization (ISH) on tissue GC microarray tissues, in addition to reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
|
30988810 |
2019 |